Biotech entity
All 1 tracked stories fall under one category: fda-approval. GNTbm-38 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. GNTbm appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. GNTbm-38 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. GNTbm appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GNTbm. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated preliminary safety and pharmacokinetic results from Phase I.
Trial Initiation
Expected commencement of patient recruitment and site activation.
FDA IND Approval
GNTbm receives official clearance to begin Phase I trials for GNTbm-38.
GNTbm has received Investigational New Drug (IND) approval from the U.S. FDA to initiate Phase I clinical trials for its self-developed anti-cancer therapy, GNTbm-38. This milestone marks the company's formal entry into the U.S. clinical landscape, targeting advanced malignancies with its proprietary therapeutic candidate.
GNTbm is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
